Image via discovered:koreaherald.com
Samsung Biologics: Partnership
Samsung Biologics attending BIO International Convention 2026 in San Diego with a large 140 sq meter booth, explicitly targeting global partnerships and contract expansion as a core objective.
Source: discovered:koreaherald.com
The leadership read
Alliances like this can broaden biotech & pharma commercial leadership bench strength.
Market context: This lands while the Talent Market Index reads 113.7 (Hot) — up 13.8 versus the prior month — and Americas signal share is easing (-3pts).
Samsung Biologics: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 21 tracked companies; 0.1% of MitchelLake's Americas signal flow.
MitchelLake in this thematic
More signals across Biotech & Pharma
Partnership · Americas
Ratio Therapeutics →Ratio Therapeutics expanded manufacturing collaboration with PharmaLogic to add capacity and redundancy for clinical development of lead radiotherapeutic candidate BOSTON
Partnership · Americas
Bristol Myers Squibb →Bristol Myers Squibb entered into a major alliance with Chinese pharmaceutical firm Hengrui involving up to 13 drugs and valued at up to $15.2 billion. This represents significant international collaboration in drug development and commercialization.
Partnership · Americas
BioDuro →BioDuro forms strategic partnership with CTI Biotechnology to create integrated platform from discovery to IND submission for preclinical drug development
Product Launch · Americas
Neurocrine Biosciences →Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Ma Activity · Americas
Biogen →Biogen agreed to acquire RayThera Inc., adding multiple immunology assets including a lead asset entering Phase 1 clinical development.
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Intelligence powered by Autonodal ↗